Ad Box 01 - HTML1

Logo - HTML2

Small Menu - HTML3

Search - HTML4

Ad Box 2 - HTML8

Recent Posts Slider - HTML22

Court bucks judicial trend of approving big Pharma's anticompetitive generic drug deals

They cost consumers about $3 billion a year, the Federal Trade Commission (FTC) believes they are illegal, a bipartisan coalition of Senators has introduced legislation to abolish them, and President Barack Obama opposes them, but because federal judges are split on the issue, “pay-for-delay” agreements are widely used in the pharmaceutical industry. Pay-for-delay refers to deals in which a drug manufacturer with a name-brand product funnels a share of its profits to another drug maker in return for its promise not to produce a generic equivalent.